A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

September 30, 2013

Conditions
Prophylaxis for the Measles Infection
Interventions
BIOLOGICAL

PMV via Puffhaler® device

The vaccine will be administered via a Puffhaler® device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.

BIOLOGICAL

PMV via SoloventTM device

The vaccine will be administered via SoloventTM device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.

BIOLOGICAL

Licensed Subcutaneous Measles Vaccine

This is a licensed formulation containing the live attenuated Edmonston Zagreb virus. A single dose of 0.5 ml will be given subcutaneously.

Trial Locations (1)

411018

Department of Pediatrics, Padmashree Dr. D. Y. Patil Medical College, Pune

All Listed Sponsors
collaborator

University of Colorado, Boulder

OTHER

collaborator

Centers for Disease Control and Prevention

FED

lead

Serum Institute of India Pvt. Ltd.

INDUSTRY

NCT01557699 - A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices | Biotech Hunter | Biotech Hunter